[Solved] Levetiracetam and psilocybin from magic mushrooms or truffles

There is no direct interaction between levetiracetam and psilocybin. However, people with epilepsy should be very cautious because for some people, psilocybin can lower the epileptic seizure threshold and lead to seizures. Scientific data on psychedelics and seizures are scarce.. In clinical trials, people with (a history of) epilepsy are usually excluded.

To date, no clinical trial or animal model has convincingly demonstrated that classic psychedelics spontaneously trigger seizures in people without epilepsy. In fact, a scoping review (2024) concluded that psychedelics do not significantly increase the risk of seizures in healthy people, as long as no other drugs are used at the same time.

For people with epilepsy is it a more sensitive matter and are these the important findings:

1. Case reports and clinical observations: There are case reports of seizures after psychedelics, but often dehydration, other substances (e.g., alcohol, MDMA), or medication played a role.. For example, an attack occurred with LSD use together with an SSRI. and some children suffered seizures after accidental MDMA ingestion. These reports do not prove that psychedelics in themselves were the cause. They lack evidence that psilocybin is a leading cause.

2. Possible effect lower threshold: A recent case from 2023 showed that a high dose of magic mushrooms (approx. 3.6 g or about 35 mg psilocybin) in a patient with treatment-resistant epilepsy led to a cluster of 32 epileptic episodes in a single day.. This man had an RNS neurostimulator and used levetiracetam and pregabalin, among others, and the recorded seizures were significantly higher than his normal frequency.. Interestingly enough, a caused low dose (1.5 g or approximately 15 mg psilocybin) no increase in seizures in the same patient. This suggests that high psychedelic doses can lower the seizure threshold in someone with epilepsy, while low doses possibly less effect have on the threshold. Other sources also confirm that especially high dosages can be problematic: a review notes that in people with epilepsy, psychedelics may more frequently lead to a worsening of seizures, especially in high doses, while low doses produce little change.

3. Possible effect increase threshold micro to low dosage: On the other hand, preclinical research hint at a possible anti-epileptic effect of psychedelics in low doses. A mouse study (2025) found that psilocin (the active metabolite) in moderate doses (3 mg/kg) protected against provoked seizures (PTZ and electroshock models). This dose had anticonvulsive properties via, among others,. 5-HT1a-receptors and the cannabinoid CB1 receptor, independent of the classic 5-HT2A psychedelic pathway. This indicates that subpsychedelic doses possibly raise the threshold without hallucinogenic effects. Other animal studies (for example, with the psychedelic tryptamine DPT) also show a reduction in seizures.

In summary: There is no straightforward answer. At healthy people Classic psychedelics rarely seem to lead to seizures (only ~0.8% of nearly 6,000 reported psilocybin withdrawals were accompanied by a seizure, often in combination with other factors. people with epilepsy However, individual differences exist: some experience no increase or even relief, while others report a clear attack trigger at higher doses. The attack threshold can therefore be reduced by psilocybin in high doses – especially in individuals with a predisposition – but there is also an indication that very low doses may do no harm or even have a protective effect. As a precaution, it is often assumed in a clinical context that all psychedelics *can* lower the threshold, hence the exclusion of epilepsy patients from studies and warnings from neurologists.

The current medical consensus is therefore:
psilocybin can lowering the seizure threshold in people with epilepsy, especially at higher dosages, and is therefore a real risk.

Does it make sense to temporarily stop levetiracetam for a truffle session?

This will be medically advised against.

Levetiracetam has a half-life of approximately 7 hours and is pharmacologically speaking, after approximately 48 hours largely from the body. In theory, that would be the “wash-out”. In practice, however, this is not a safe alternative, because:

1. It temporarily stopping anti-epileptic drugs is itself a strong seizure trigger, often more dangerous than a possible interaction.

2. Attacks can actually occur during or shortly after abrupt stopping, even if someone had been seizure-free for a longer period of time.

3. If a seizure occurs during a psychedelic session, it is especially dangerous due to disorientation and physical risks.

4. In a subset of patients, complete seizure freedom returns. not directly back after restarting the medication.

There exists no evidence-based safe stopping period in which a truffle session can be considered responsible. From a neurological perspective, the risk of stopping outweighs the potential benefit of the experience.

Final conclusion

There is no direct interaction between psilocybin and levetiracetam at a pharmacological level. Nevertheless, the use of magic mushrooms or truffles in someone with epilepsy remains unsafe, especially at normal to high dosages, because psilocybin can lower the seizure threshold and levetiracetam does not completely neutralize this risk. It is precisely the unpredictability of whether psilocybin leads to a lower or higher chance of seizures that leads to a negative recommendation (just to be safe). Does someone still want a truffle session if you do so, it can still be done under supervision with a low dosage, despite the negative advice.

It temporarily stopping levetiracetam to do a truffle session is no safe alternative and actually increases the risk of seizures. From a neurological and clinical perspective, the most responsible advice is therefore: Do not use psilocybin as long as levetiracetam is required for epilepsy control.

Disclaimer

This is not personalized medical advice for you. Always contact your treating physician and discuss this text. Never stop taking medication abruptly without the advice of a medical specialist!

How does levetiracetam work, and which neurotransmitters are affected?

Levetiracetam is an antiepileptic drug with an atypical and relatively selective mechanism of action. Unlike classic agents, it does not primarily affect ion channels such as sodium or calcium channels, but rather acts on synaptic signal transduction.

Binding to SV2A as a core mechanism

The primary mechanism of action of levetiracetam is its binding to synaptic vesicle protein 2A (SV2A). This protein is located on presynaptic vesicles and is essential for the release of neurotransmitters into the synaptic cleft. Through this binding, levetiracetam stabilizes vesicular release, particularly during periods of high neuronal activity. This suppresses pathological, hypersynchronous discharges without completely blocking normal signal transmission.

Affected neurotransmitters

Levetiracetam does not act as a direct agonist or antagonist of one specific neurotransmitter, but indirectly modulates multiple systems.

Glutamate
The most important indirect influence is on glutamate, the principal excitatory neurotransmitter in the brain. Levetiracetam reduces the excessive presynaptic release of glutamate during epileptic activity. This lowers neuronal hyperexcitability and prevents excitotoxicity, without severely suppressing basal glutamatergic transmission.

GABA
GABA is the most important inhibitory neurotransmitter. Levetiracetam does not directly increase GABAergic inhibition, as benzodiazepines do, but can indirectly enhance the effectiveness of existing GABA signaling. This occurs because the balance shifts towards inhibition when excitatory glutamate release is inhibited.

Glycine
There are indications that levetiracetam may also cause a slight modulation of glycine-mediated inhibition, particularly in the brainstem and spinal cord, although this effect is clinically less prominent than with glutamate and GABA.

Calcium-dependent neurotransmitter release
Levetiracetam indirectly influences calcium-dependent processes through interaction with SV2A. As a result, neurotransmitter release is tempered at elevated intracellular calcium concentrations, which is particularly relevant during rapid, repetitive discharges.

Monoamines (serotonin, dopamine, norepinephrine)
Levetiracetam has no strong direct influence on monoaminergic receptors. However, indirect effects on serotonergic and dopaminergic circuits have been described, particularly in limbic brain regions. This indirect modulation is seen as a possible explanation for mood and behavioral changes, such as irritability, anxiety, or depression.

Effect on neuronal networks

Levetiracetam primarily acts as a network stabilizer. It dampens pathological synchronization of neuronal networks, particularly in cortical and hippocampal circuits involved in epileptic seizures. Consequently, the drug suppresses seizures without significantly reducing general brain activity, which explains the relatively favorable cognitive profile.

Clinically relevant summarized

Levetiracetam:

1. binds to SV2A and stabilizes synaptic vesicle release

2. reduces excessive glutamate release

3. shifts the balance indirectly towards GABAergic inhibition

4. influences calcium-dependent neurotransmitter release

5. can indirectly influence monoaminergic systems, which explains mood changes

As a result, levetiracetam is effective in various forms of epilepsy, with few medication interactions and limited sedation, but with attention to possible psychological side effects.

Can levetiracetam be taken with psilocybin?

Combining psilocybin (magic mushrooms or truffles) with levetiracetam is not properly investigated and is used in conventional medicine not recommended as safe, especially not in people who use levetiracetam for epilepsy or a reduced seizure threshold. There is no known direct pharmacological interaction, but the risk lies mainly in the increasing the risk of epileptic activity. It Temporarily stopping levetiracetam to have a truffle session is medically strongly advised against..

Is there a direct interaction between psilocybin and levetiracetam?

There is no evidence that psilocybin and levetiracetam directly influence each other via liver enzymes (such as CYP450), protein binding, or each other's blood levels. Levetiracetam is largely renally excreted unchanged, and psilocybin (via psilocin) is rapidly metabolized. From a strictly pharmacokinetic perspective, therefore, there is no classic drug-drug interaction known.

However, that does not mean that the combination is safe.

The real risk: epileptic threshold and network excitation

Levetiracetam is prescribed to dampen neuronal hyperexcitability. Psilocybin essentially does the opposite in the brain: it increases cortical excitation, enhances neuronal flexibility, and reduces functional inhibition, primarily via 5-HT2A activation in the cortex and thalamocortical networks.

In people with epilepsy, a history of seizures, or a reduced seizure threshold, psilocybin can theoretically and clinically increase the risk of a seizure. This risk exists even if someone is “well adjusted” to medication. Levetiracetam suppresses seizures, but does not cure the underlying sensitivity.

Therefore, the following applies in the medical literature and in virtually all clinical studies with psilocybin: epilepsy and anti-epileptic drugs are exclusion criteria.

What if you temporarily stop levetiracetam?

This is the most risky scenario. Suddenly stopping levetiracetam can lead to:

1. rebound hyperexcitability

2. increased risk of (severe) epileptic seizures

3. status epilepticus, even in people who have been seizure-free for a long time

Levetiracetam has a relatively short half-life (approximately 6–8 hours), but it The neuroprotective effect disappears faster than the brain can adapt.. Temporarily stopping “for a session” is therefore medically irresponsible, even if this were only one or two days.

There is no safe “wash-out period” during which you could use psilocybin without risk if you are using or need levetiracetam.

When could psilocybin actually be considered?

Only in the hypothetical case that levetiracetam is no longer needed, for example, because it was once prescribed off-label and a neurologist considers stopping it medication-free to be fully justified. In that case, it must first be established over an extended period without medication that there is no longer an increased risk of seizures. This is a medical trajectory, no practical break.

Conclusion

Psilocybin has no known direct chemical interaction with levetiracetam, but does form a real neurological risk in people who use this medication. Temporarily stopping levetiracetam to do a truffle session is inadvisable and potentially dangerous. From a medical and harm-reduction perspective, the following applies: No psilocybin as long as levetiracetam is indicated..